CBMG Raises $120 Million for Clinical Trials of Cellular Immunotherapies
October 01, 2021 at 02:47 AM EDT
CBMG, a Maryland-Shanghai biopharma, raised $120 million in a Series A funding to develop its immunoncology programs. CBMG develops novel cellular immunotherapies to treat cancer and degenerative diseases, with an emphasis on CAR-T products for cancer and stem cell therapies for degenerative diseases. In February 2021, CBMG completed a $383 million go-private transaction from its previous NASDAQ listing. The A round was led by AstraZeneca-CICC Fund, Sequoia Capital China and Yunfeng Capital. More details.... Share this with colleagues: // //
